Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etoposide Phosphate

FDA-approved product (injectable, injection), marketed as Etopophos Preservative Free.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Etoposide Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lung cancer
  • Lung neoplasm
  • Neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Podophyllotoxin derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etoposide Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etoposide Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

    NCT00504140 · start 1996-11

    Registered record
    Registry ID
    NCT00504140
    Conditions
    Osteosarcoma
    Interventions
    Etoposide; Interferon Alpha
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-11
    Completion
    2009-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteosarcoma
    InterventionEtoposide; Interferon Alpha
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

    NCT00002701 · start 1995-10

    Registered record
    Registry ID
    NCT00002701
    Conditions
    Leukemia
    Interventions
    busulfan; cyclophosphamide; cytarabine; etoposide; idarubicin; mercaptopurine; methotrexate; mitoxantrone hydrochloride; thioguanine; tretinoin; allogeneic bone marrow transplantation; autologous bone marrow transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    1995-10
    Completion
    Not recorded
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionbusulfan; cyclophosphamide; cytarabine; etoposide +9 more
    PhasePhase 3
    Registry statusUnknown

  • Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

    NCT00002836 · start 1995-09-26

    Registered record
    Registry ID
    NCT00002836
    Conditions
    Breast Cancer
    Interventions
    Filgrastim (G-CSF); Carmustine; Cisplatin; Cyclophosphamide (CTX); Etoposide; Thiotepa; Peripheral Blood Stem Cell Transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-09-26
    Completion
    2006-03-09
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionFilgrastim (G-CSF); Carmustine; Cisplatin; Cyclophosphamide (CTX) +3 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

    NCT00002596 · start 1994-09

    Registered record
    Registry ID
    NCT00002596
    Conditions
    Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor
    Interventions
    bleomycin sulfate; filgrastim; carboplatin; cisplatin; cyclophosphamide; etoposide; autologous bone marrow transplantation; bone marrow ablation with stem cell support; conventional surgery; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1994-09
    Completion
    2006-07
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor
    Interventionbleomycin sulfate; filgrastim; carboplatin; cisplatin +7 more
    PhasePhase 3
    Registry statusCompleted

  • Dose-Dense Therapy in Aggressive Lymphoma

    NCT00517894

    Registered record
    Registry ID
    NCT00517894
    Conditions
    Lymphoma
    Interventions
    CEOP/IMVP-Dexa chemotherapy
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionCEOP/IMVP-Dexa chemotherapy
    PhaseNot recorded
    Registry statusNo longer available